Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.36 |
| ▸ | TLR2 | O60603 | 1/20 | 0.36 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.35 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2926699 | 0.81 | KMT2A (0.41) | KMT2AMALT1TLR2TLR1MDM2 | |
| SCHEMBL2252447 | 0.81 | KMT2A (0.41) | KMT2A | |
| SCHEMBL2247593 | 0.81 | KMT2A (0.41) | KMT2A | |
| SCHEMBL2249667 | 0.80 | KMT2A (0.42) | KMT2A | |
| SCHEMBL31714189 | 0.78 | KMT2A (0.45) | KMT2AMALT1TLR2TLR1MDM2 | |
| SCHEMBL2250139 | 0.76 | KMT2A (0.43) | KMT2A | |
| SCHEMBL2928612 | 0.75 | KDM4E (0.39) | KMT2AMALT1TLR2TLR1MDM2 | |
| SCHEMBL25671629 | 0.75 | KMT2A (0.48) | KMT2AMALT1TLR2TLR1MDM2 | |
| SCHEMBL2928219 | 0.74 | KMT2A (0.42) | KMT2ATLR2TLR1MDM2 | |
| SCHEMBL3579032 | 0.74 | HDAC4 (0.49) | KMT2ATLR2TLR1EPHX1MDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1675824-B1 | SOMATOSTATIN RECEPTOR 1 AND/OR 4 SELECTIVE AGONISTS AND ANTAGONISTS | WURSTER SIEGFRIED (FI) | 2010-09-29 | — | — | EP | disclosed |
| US-7741362-B2 | Somatostatin receptor 1 and/or 4 selective agonists and antagonists | SIEGFRIED WURSTER (FI) | 2010-06-22 | — | — | US | disclosed |
| US-20100004339-A1 | Somatostatin Receptor 1 and/or 4 Selective Agonists and Antagonists | OY JUVANTIA PHARMA LTD. (FI) | 2010-01-07 | — | — | US | disclosed |
| US-20070129422-A1 | Somatostatin receptor 1 and/or 4 selective agonists and antagonists | OY JUVANTIA PHARMA LTD (FI) | 2007-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129422-A1 | Somatostatin receptor 1 and/or 4 selective agonists and antagonists | SSTR4, SSTR1, SSTR3 | KMT2A 2112/4885MALT1 1696/4885TLR2 1820/4885 |
| US-20100004339-A1 | Somatostatin Receptor 1 and/or 4 Selective Agonists and Antagonists | SSTR4, SSTR1, SSTR3 | KMT2A 2112/4885MALT1 1696/4885TLR2 1820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.